Overview

Eligibility

North American-based Junior Faculty and Fellows (MDs, MD/PhDs) involved in research related to EGFR-mutated adenocarcinoma of the lungs. We encourage thoracic oncologists, surgeons, radiation oncologists, pathologists, and related lab-based and translational researchers to submit!

• Junior Faculty (Instructors or Assistant Professors)
• Trainee (Must be enrolled in an ACGME-accredited fellowship program or PhD postdoctoral fellowship)
• PhD Candidates (A limited number of applicants that are conducting lab-based EGFR NSCLC research will be considered)

Candidates must be based in North America and training must be completed at a North American-based institution.

All work must be unpublished original research in an area related to EGFR-mutated lung cancer. For junior candidates who do not yet have a scientific abstract to submit, we will also accept a career statement highlighting your goals and trajectory as related to this area, previously published information, journal club presentation, or other like projects representing professional development.

Abstracts to be presented at future medical meetings are eligible for submission.

Abstract Policies & Procedures

• Only one abstract submission per Young Investigator will be accepted.
• Abstracts must conform to the abstract preparation instructions. Those that do not may be rejected.
• Only original work completed by the Young Investigator will be accepted.
• All accepted abstracts will be published in an electronic program to be provided to all attendees. The publication of electronic handout materials will not preclude publication or presentation elsewhere.

Selection Process

Submission deadline is Friday, August 8, 2025

• Expert Faculty Judges will review and score all submissions. Number of abstracts to be selected for presentation will depend on quantity and quality of abstracts received.
• Young Investigators selected for participation will present their abstracts in an 8-minute oral presentation at the meeting with 7 minutes of Q&A.